Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

• Published in: The Lancet (British edition) Vol. 398; no. 10313; pp. 1811 - 1824
• Main Authors: Del Prato, Stefano, Pavo, Imre, Weerakkody, Govinda J, Yang, Zhengyu, Aizenberg, Diego, Wynne, Alan G, Wiese, Russell J, Arora, Samir, Calderon, Rafael B, Butuk, David J, Chaychi, Leila, Curtis, Brian M, Chochinov, Ronald, Chow, Christopher, Cone, Clancy L, Dungan, Kathleen, Gaudiani, Linda, Herandez-Vazquez, Luis, Hsia, Stanley H, Kutner, Mark E, Loy, Juan, Miranda, Francisco G, Oliver, Michael J, Parke, Michael T, Philis-Tsimikas, Athena, Rosenstock, Julio, Sorial, Ehab, Stonesifer, Larry D, Stringam, Stanley, Van, Joanna T, Vazquez-Tanus, Jose B, Reyes, Ramon, Karimjee, Najmuddin, Martin, Earl E, Fraser, Neil J, Bhargava, Anuj, Billings, Liana, Walsh, Patrick, Shubrook, Jay, Knouse, Albert B, Mayfield, Ronald K, Bitar, Fahed G, de la Cuesta, Carmen, Morales Portillo, Cristobal J, Quesada Charneco, Miguel, Tofe Povedano, Santiago, Vazquez, Luis, Soto Gonzalez, Alfonso, Ciomos, Daniela, Neacsu, Valentina, Stern, Naftali, Sofer, Yael, Sack, Jessica, Tirosh, Amir, Shehadeh, Naim, Darawsha, Mahmud, Skripova, Dasa, Pavleova, Eva, Kubincova, Ludmila, Merciakova, Martina, St-Amour, Eric, Yared, Zeina, Blouin, Francois, Aggarwal, Naresh K, Bajaj, Harpreet, Tailor, Chetna, Egan, Alan, St.Onge, Natasha, Borges, Joao L C, Franco, Denise R, Souza, Filipe D, Russo, Luis Augusto T, Sassone, Sonia A, Steinacher, Andrea, Perez Manghi, Federico C, Orio, Silvia I, Gelersztein, Elizabeth, Fretes, José O, Calella, Pedro R F, Zaidman, Cesar J, Chertkoff, Alejandro, Gonzalez Galvez, Guillermo, Calvo, Cesar G, Sowinski, Dariusz, Jozefowska, Malgorzata, Skokowska, Ewa, Modzelewska, Anna, Gilfillan, Christopher, Morbey, Claire, Kaur, Kamal, Kemp, Laurence, Shea, Antony J, Kunitsyna, Marina A, Ou, Horng-Yih, Chen, Jung-Fu, Hwu, Chii-Min, Doupis, John, Pagkalos, Emmanouil, Mouslech, Zadalla
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 13.11.2021; Elsevier Limited
• Subjects: Adult; Aged; Angina; Antidiabetics; Appetite loss; Blood Glucose; Blood pressure; Body Weight - drug effects; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - epidemiology; Cerebral infarction; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; Diarrhea; Fasting; Female; Gastric Inhibitory Polypeptide - adverse effects; Gastric Inhibitory Polypeptide - therapeutic use; Glucagon; Glucose; Glucose transporter; Glycated Hemoglobin A - analysis; Health risks; Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents - therapeutic use; Insulin; Insulin Glargine - therapeutic use; Interactive systems; Kidney diseases; Male; Metformin; Middle Aged; Myocardial infarction; Nausea; Risk management; Safety; Safety measures; Sulfonylurea; Vomiting; United States > US; Indianapolis Indiana

We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medications. This o...